Both iPSCs and iPSC-EVs preserved viable myocardium in the infarct zone, whereas reduction in apoptosis was significant with iPSC-EVs. iPSC injection resulted in teratoma formation, whereas iPSC-EV injection was safe. 
B
ecause the adult mammalian heart possesses limited regenerative capacity after injury, cell therapy has emerged as a potential approach for repair of the infarcted heart. Several adult stem and progenitor cells from various sources have already been tested in patients, albeit with modest benefits. 1 Although induced pluripotent stem cells (iPSCs) offer exciting opportunities for tissue restoration, recent evidence indicates that in addition to cellular replacement, paracrine factors released by injected cells are also important for cell-based heart repair. 2 These paracrine factors may be secreted directly from the transplanted cells or released as cargo in tiny membrane-enclosed structures termed extracellular vesicles (EVs). 2, 3 Given the potential of both iPSCs and iPSC-derived EVs (iPSC-EVs) for myocardial repair, there is a strong rationale to directly compare the safety and reparative efficacy of these 2 approaches.
EVs represent small (30-1000 nm) vesicles released by cells either by outward budding from the plasma membrane or via exocytosis. 4 Upon shedding, EVs may fuse with the recipient cells directly or after endocytosis followed by the release of contents or interact with target cells by receptor-ligand interactions. 5, 6 Because EVs carry proteins, mRNAs, and miRNAs, from their parental cells, they represent an important component of paracrine signaling and cell-to-cell communication. 7 Although the regenerative abilities of EVs harvested from mesenchymal stem cells and endothelial and cardiac progenitors have been reported, [8] [9] [10] the biological basis of EV actions needs further elucidation. Thus, another major rationale for this study was to characterize the molecular contents of EVs with regard to potential paracrine activities relevant for myocardial repair. Finally, although iPSCs have been known to produce teratomas, 11 the safety of iPSC-EVs remains unknown. Accordingly, we meticulously characterized the morphology and contents of iPSC-EVs with a multi-instrumental approach, examined their biological function in vitro, and compared head-to-head, for the first time, the safety and efficacy of iPSC-EVs with their parental iPSCs for cardiac repair in vivo. Our results show that iPSC-EVs carry unique sets of proteins and regulatory miRNAs and impact by angiogenic capacity, migratory activity, and survival of cardiac endothelial cells (CECs) in cytotoxic environment. In vivo, injection of iPSC-EVs after acute myocardial infarction (MI) improves left ventricular (LV) function and remodeling. Importantly, we provide evidence that although injection of iPSCs leads to tumor formation, the use of EVs derived from these cells is safe.
Methods
An expanded methods section is available in the Online Data Supplement.
The authors declare that all data that support the findings of this study are available within the article and its Online Data Supplement.
The present study was performed in accordance with the guidelines of the Animal Care and Use Committee of the University of Kansas Medical Center and with the Guide for the Care and Use of Laboratory Animals (Department of Health and Human Services, publication No. [National Institutes of Health] 86-23) and also in accordance with the Polish and European legislation after approval by the First Local Ethical Committee on Animal Testing at the Jagiellonian University. The data that support the findings of this study are available from the corresponding authors on reasonable request.
iPSC Generation
Murine fibroblasts were transfected with lentivirus expressing Oct4, Sox2 (sex-determining region Y-box 2), and Klf4. iPSC colonies were picked, further expanded, and adapted to serum-free conditions. Colonies with high contents of pluripotency-associated transcripts (Online Figure  I) were chosen for further studies. iPSCs were phenotyped by flow cytometry and immunocytochemistry following standard protocols.
EV Purification
EVs were prepared from the culture supernatant of iPSCs using a protocol optimized in our laboratory (Online Figure II) . 12 Nanoparticle
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Novelty and Significance
What Is Known?
• Induced pluripotent stem cells (iPSCs) differentiate into numerous cell types and, therefore, hold great promise for heart regeneration.
• Extracellular vesicles (EVs), including the fraction of exosomes derived from various stem cells, have been shown to ameliorate myocardial ischemia/reperfusion injury and promote cardiac repair.
• The comparative safety and efficacy of iPSCs and iPSC-derived EVs (iPSC-EVs) for infarct repair have not been examined.
What New Information Does This Article Contribute?
• The molecular cargo within iPSC-EVs includes numerous miRNAs that are present in iPSCs and several additional miRNAs that are enriched specifically in EVs. These miRNAs are known to promote cellular proliferation and differentiation, enhance angiogenesis, and prevent apoptosis.
• The proteomic analysis of EVs revealed molecules that stimulate cardiomyogenesis; promote cardiac, endothelial, and smooth muscle cell proliferation; and protect against oxidative damage.
• The iPSC-EVs induced angiogenic, migratory, and antiapoptotic properties in cardiac endothelial cells in vitro and induced superior infarct repair in vivo compared with iPSCs. iPSC injection resulted in teratoma formation, whereas EV injection did not produce any tumor.
iPSCs, which are able to give rise to numerous cell types, have shown great promise for heart regeneration. EVs, minute membrane-enclosed droplets released by mammalian cells, have also been shown to ameliorate myocardial ischemia/reperfusion injury. However, the myocardial reparative abilities of EVs derived from iPSCs have not been directly compared with the source iPSCs. The results from quantitative RT-PCR and proteomic analyses revealed that EV cargo is enriched with numerous molecules that impart cytoprotective and angiogenic benefits to cardiac cells. After ischemia/reperfusion and transplantation in vivo, both iPSC-and iPSC-EV-treated mice exhibited improved LV function compared with vehicle-treated mice; however, iPSC-EVs induced greater functional benefits and resulted in superior perfusion in the infarct zone and prevented apoptosis. iPSC injections resulted in teratoma formation, whereas iPSC-EV injections were safe. These observations indicate that iPSC-EVs confer cytoprotective properties to cardiac cells in vitro and induce superior cardiac repair in vivo without the risk of teratoma formation seen with parental iPSCs. Thus, iPSC-EVs offer a safer alternative for potential therapeutic applications in patients with ischemic myocardial damage.
tracking analysis, atomic force microscopy, high-resolution flow cytometry, and quantitative RT-PCR were used to characterize EVs. MicroRNA expression profiling was performed using quantitative RT-PCR.
EV Protein Analysis by LC-MS/MS
After lysis, samples from iPSCs and iPSC-EVs for LC-MS/MS (liquid chromatography-mass spectrometry) analysis were prepared using the FASP (filter-aided sample preparation) method. 13 Peptide fractions were analyzed using Q Exactive high-resolution mass spectrometer coupled with nanoHPLC. The data were analyzed using Proteome Discoverer 1.4 and a MASCOT server against the Swissprot_201509 database. Search result validation was performed using Percolator algorithm.
14 Gene ontology (GO) was analyzed using FatiGO software.
Assessment of EV Function In Vitro
Murine CECs and fluorescent EVs were used for cellular uptake studies. Capillary tube formation assay was performed on Matrigel. The movement of CECs was time-lapse recorded, and cell trajectories were constructed and analyzed. CEC viability and apoptosis were analyzed by flow cytometry.
Experimental Protocol for the In Vivo Studies
A total of 43 wild-type (C57BL6/J) mice were used for the in vivo studies. The experimental protocol is summarized in Online Figure  III . All mice underwent a 30-minute coronary occlusion followed by reperfusion. After 48 hours, chest was reopened, and mice received intramyocardial injection of vehicle (group I), iPSCs (group II), or iPSC-EVs (group III). Echocardiographic studies were performed 4 days before coronary occlusion/reperfusion, at 48 hours after cell injection, and 35 days after MI using a Vevo 2100 Ultrasound System.
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Morphometry and Immunohistochemistry
After 35 days, mice were euthanized and hearts harvested and formalin fixed. All morphometric and immunohistochemical analyses were performed on 4-μm thick sections using standard methods. 15, 16 Capillary density was quantitated in isolectin-B4-stained sections.
Interstitial collagen was quantified on images taken from the nonischemic myocardium of picrosirius red-stained sections using ImagePro Plus. Myocyte apoptosis was quantitated using TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) assay.
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Statistical Analysis
Data are expressed as mean±SEM or SD as indicated. The impact of iPSC-EVs on the formation of CECs into capillary-like structures was evaluated using the Mann-Whitney U test. The movement parameters for CECs were compared using the Student t test. Morphometric and histological data were analyzed using 1-way ANOVA, whereas serial echocardiographic parameters were analyzed using 2-way (time and group) ANOVA followed by Student t tests with the Bonferroni correction. Comparisons between 2 groups were performed by unpaired Student t test. P values <0.05 were considered statistically significant. Statistical analyses were performed using the GraphPad Prism (version 4.03; GraphPad Software, Inc, La Jolla, CA) and SPSS software, version 22.0 (IBM, Armonk, NY).
Results
In Vitro Studies iPSCs Expanded in Optimized Serum-and Feeder-Free Conditions Maintained Pluripotency as a Source of Purified EVs
To obtain pure iPSC-EV specimens without contamination of nanoparticles that originated from other cells or from serum present in the culture system, 17 all iPSC clones were expanded in optimized culture conditions in serum-free media without feeder layer cells. Using a multi-instrumental approach, we confirmed the presence of a stable pluripotent phenotype in the selected iPSC lines (Online Figure I) . iPSCs expressed pluripotency-related markers, including Oct3/4A, Nanog, Sox2, and Rex1, at the mRNA and protein levels, as well as placental alkaline phosphatase (Figure 1A through 1C; Online Figure I ). iPSCs also expressed adhesion molecules and growth factor receptors considered important for stem cell activities, including CD49e, CD29, CD105, and CD117, which may be potentially transferred to iPSC-EVs ( Figure 1D ). These results provide evidence that pluripotent iPSCs can be effectively cultured in feeder-and serum-free conditions for uncontaminated harvest of EVs.
Next, iPSC-EVs were successfully isolated from the iPSCconditioned media by a sequential centrifugation procedure, including ultracentrifugation, resulting in EV specimens containing both microvesicles and exosome fractions (Figure 2A) . Importantly, we confirmed the presence of iPSC-EVs according to the current recommendations 18 by examining their (1) size distribution by nanoparticle tracking analysis platform, (2) high-resolution morphology and membrane elasticity by atomic force microscopy, and (3) expression of EV-related antigens (eg, CD9 and CD81 tetraspanins) by Western and high-resolution flow cytometry ( Figure 2B through 2E) . Moreover, we confirmed the iPSC origin by detecting transcripts for pluripotent transcription factors Oct3/4, Nanog, and Rex1 ( Figure 2F ). These data confirm that the iPSC-EV specimens used in further studies represent homogenous vesicular fractions that exhibit common EV morphology and antigen expression, along with the presence of iPSC-derived markers.
iPSC-EVs Contained iPSC-Specific Molecules and Were Enriched in a Distinctive Set of miRNAs and Proteins
To identify the molecular contents, which may be responsible for the biological activity and regenerative capacity of EVs, we next performed global miRNA and proteomic profiling of iPSC-EV specimens. Among 282 miRNAs detected in iPSCs, 199 were also present in iPSC-EVs ( Figure 2G ), indicating efficient transfer of these regulatory transcripts from the parental iPSCs to EVs. Importantly, miRNAs belonging to the miR-290-295 cluster regulating pluripotency, 19 including miR-292, -293, -294, and miR-295, were abundant not only in the parental cells but also in the iPSC-EVs (Online Tables I and II) . Moreover, among the miRNAs present in both iPSCs and iPSC-EVs, we found miR-19b, miR-20a, miR-126-3p, miR-130a-3p, miR-210-3p, and the longevimir cluster miR-17-92 reportedly involved in the promotion of angiogenesis, adaptation to hypoxic stress, regulation of cell cycle, mammalian development, and aging. 20 Moreover, certain miRNAs were differentially expressed in iPSCs and iPSC-EVs ( Figure 2G ; Online Tables I and  II) . Indeed, 33 miRNAs were detected only in iPSC-EVs by qPCR-based method ( Figure 2G ; Online Table III) , which suggests their high enrichment during EV production and release by iPSCs-a phenomenon suggested previously. 21 MicroRNAs enriched in EVs, including let-7, miR-145, miR-17-92 cluster, and ESC-specific miR-302a-5p, have been suggested to play a role in late developmental timing; regulation of cell proliferation, differentiation, apoptosis, and maintenance of self-renewal and pluripotency 19, 20, 22 ; and may exert possible beneficial effects on myocardial tissue. Moreover, the heatmap analysis indicated other signaling pathways potentially regulated by miRNA contents of iPSC-EVs, including Wnt, PI3K-Akt, and MAPK (mitogen-activated protein kinase) pathways, which are involved in the regulation of actin cytoskeleton, focal adhesion, and ECM-receptor interactions (Online Figures IV and V) . Moreover, additional examination by Ingenuity Pathway Analysis tool (Qiagen) identified several miRNAs abundant in iPSC-EVs, including miR-294, miR-16, miR-34, and miR-20, which may regulate VEGFA (vascular endothelial growth factor A) signaling, thereby potentially enhancing angiogenesis (Online Figure VI) .
Next, we performed high-throughput global proteomic analysis of iPSCs and iPSC-EVs using mass spectrometry.
Importantly, the number of proteins identified in challenging iPSC-EV samples and also in iPSC samples was highly reproducible and consistent across all replicates, confirming the high quality of samples and proteomic procedures ( Figure 3A ). Proteins within each group (iPSCs or iPSC-EVs) were considered for analysis only when proteins were reliably identified within the samples, ie, (1) in each replicate of the group and (2) in at least 2 of 3 replicates, on the basis of ≥2 unique peptides. These strict analytic criteria were fulfilled by 4122 and 1965 proteins detected in iPSCs and iPSC-EVs, respectively ( Figure 3A) . Because of the high number of common proteins detected in both groups, confirming again the effective transfer of major molecular contents from the parental iPSCs to EVs, we focused our analysis on comparing the unique proteins identified in all samples of a given group and none of the samples from the other groups. A total of 1536 differential proteins were found to be present in iPSCs and 191 in iPSC-EVs ( Figure 3A) .
GO analysis for molecular function, cellular component, and biological processes related to the most apparent differences between parental iPSCs and iPSC-EVs are shown in Figure 3B through 3E and Online Figure VII . As expected, the proteins identified in iPSC-EVs were the most strongly represented (by GO terms) in plasma membrane, cytosol, and cytoskeleton but not in other organelle compartments not present in EV structure ( Figure 3C ). Importantly, the GO analysis of biological processes revealed an enrichment of differential proteins involved in response to wound healing, regulation of cell differentiation, as well as organ, anatomic structure, and multicellular organism development ( Figure 3D ; Online Figure Figure VIIIB) . Thus, proteomic data indicated that the majority of iPSC-specific proteins is transferred from the parental iPSCs to iPSC-EVs and may suggest the impact of such protein contents on several biological processes in target cells, including the ones associated with tissue repair.
iPSC-EVs Improved CEC Function by Enhancing Angiogenic Capacity, Migration, and Survival In Vitro
Increasing evidence indicates that angiogenesis is a major mechanism responsible for the improvement in LV function with cell therapy after ischemic myocardial injury. Because our data identified several miRNAs and proteins within the iPSC-EVs, which may regulate target cell function, including proliferation, differentiation, survival, and angiogenesis, we investigated the impact of iPSC-EVs on selected functions of murine CECs in vitro, with emphasis on features potentially important for heart repair. First, we confirmed that iPSC-EVs were internalized by CECs after only 1 hour of coincubation, as shown by optical orthogonal sectioning in xy axis by fluorescent microscopy ( Figure 4A ). Compared with control-untreated cells, CECs treated with iPSC-EVs exhibited greater ability to form endotubules on Matrigel by quantitative analysis ( Figure 4B ; Online Figure IX ; Online Movies I and II). These data suggest that iPSC-EVs are likely to exert proangiogenic effects after myocardial injection in vivo. Next, we addressed whether iPSC-EVs influence CEC migratory capacity, which has been reported as a crucial functional property required in wound healing, tissue repair, including myocardial regeneration, as well as during new vessel formation and maturation. 23 The quantitative analysis of recorded CEC trajectories, based on time-lapse monitoring of spontaneous unguided movement of single cells, showed greater speed of cell displacement after iPSC-EV treatment compared with controls ( Figure 4C ). This phenomenon was more pronounced and statistically significant after prolonged EV treatment, when migration was analyzed between 9 and 14 hours of CEC coincubation with iPSC-EVs. These data indicate that iPSC-EVs enhance the migratory capacity of CECs, which may augment new vessel formation and maturation after iPSC-EV transplantation in vivo.
Finally, to examine the impact of iPSC-EVs on cell survival in cytotoxic conditions that often accompany tissue injury, we used staurosporine (1 μM), a cytotoxic agent commonly used to induce apoptosis, to challenge CECs before their incubation with iPSC-EVs. We measured cell death processes, including apoptosis and necrosis, after 24 hours of coincubation of staurosporine-challenged CECs with iPSC-EVs by flow cytometry. Exposure to iPSC-EVs significantly decreased the incidence of staurosporine-induced apoptosis (38.1±4.7% versus 54.4±1.7% of cells in late apoptosis among CECs incubated with iPSC-EVs versus control-untreated cells, respectively; P<0.05; Figure 4D ). Moreover, the number of viable cells was significantly greater in samples treated with iPSCEVs (29.3±5.3%) when compared with control CECs treated with staurosporine alone (13.4±0.7%). Importantly, there was no change in the number of cells undergoing necrosis in either iPSC-EV-treated or untreated samples ( Figure 4D ). These results indicate cytoprotective and antiapoptotic effects of iPSCEVs on CECs in vitro, which may play an important role in protecting ischemic myocytes in vivo.
In Vivo Studies
Exclusions Four mice died in the perioperative period, and 3 mice died at 5, 19, and 29 days after intramyocardial injection. Eight mice were excluded from the study because of cardiac tumor formation in the iPSC-treated group, leaving a total of 9, 7, and 12 mice in vehicle, iPSC, and iPSC-EV groups, respectively (Online Table IV ).
Myocardial Infarct Size
The infarct area fraction denotes the average area of scar tissue, expressed as a percentage of the LV area in 3 LV sections 0.5 to 1.0 mm apart. The average infarct area fraction did not differ significantly among the 3 groups (Online Figure X) .
Intramyocardial Injection of iPSC-EVs Induced Greater Attenuation of LV Dysfunction
Before coronary occlusion (baseline), all parameters of LV function were similar in groups I through III ( Figure 5 ). At 48 hours after cell or EV transplantation (4 days after MI), the degree of LV dysfunction was also similar among the 3 groups ( Figure 5B and 5C), indicating that the injuries sustained during ischemia/reperfusion and intramyocardial injection were similar in all groups. In vehicle-treated (group I) mice, there was further LV functional deterioration between 4 and 35 days after reperfusion. In contrast, both iPSC-and iPSC-EV-treated mice (groups II and III, respectively) exhibited significantly improved global ( Figure 5B through 5E) LV function compared with group I at 35 days after MI. Mice in groups II and III also showed enhanced regional myocardial function in the infarct zone, as evidenced by a 10% (P<0.05) and 19% (P<0.01) greater systolic infarct wall thickness ( Figure 5A and 5F), respectively, compared with group I. The preservation of LV function was significantly greater in hearts injected with iPSC-EVs compared with iPSC-injected hearts ( Figure 5B and 5C ). In addition, mice in group III also exhibited smaller LV end-systolic volume compared with vehicletreated mice ( Figure 5E ).
Intramyocardial Delivery of iPSCs and iPSC-EVs Halted LV Remodeling and Hypertrophy
The echocardiographic measurements of LV remodeling at 35 days mirrored the observations on LV function. The LV end-diastolic diameter was significantly smaller in groups II and III compared with group I (Figure 6B ).
Also, compared with group I, the infarct wall thickness in diastole was significantly greater both in groups II and III ( Figure 6C ), indicating superior infarct repair. The posterior LV wall thickness was smaller in groups II and III compared with group I (Figure 6D ), indicating less hypertrophy of the viable myocardium. Although the improvements in LV end-diastolic diameter and infarct wall thickness were numerically greater in iPSC-EV-compared with iPSC-treated hearts, the differences were not statistically significant. 
Intramyocardial Delivery of iPSC-EVs Attenuated LV Hypertrophy
To assess the impact of therapy on the myocardium, interstitial fibrosis was carefully quantitated. At 35 days after MI, interstitial fibrosis was similar in vehicle-and iPSC-treated hearts ( Figure 6E and 6F) . Although not statistically significant, in mice treated with iPSC-EVs, interstitial fibrosis was 11% less compared with vehicle-treated hearts ( Figure 6E and 6F) . At 35 days after MI, the echocardiographically estimated LV mass increased significantly in all groups compared with baseline values. Compared with group I, the LV mass was 16% (P<0.05) smaller in iPSC-EVs-treated mice ( Figure 6G ). Taken together, these data indicate that injection of iPSC-EVs attenuates the adverse adaptations in surviving LV myocardium after MI.
Effects of iPSC and iPSC-EV Therapy on Myocardial Capillary Density
Because myocardial vascularity plays an important role in cardiac repair post-MI, we assessed capillary density in the infarct zone, borderzone, and nonischemic zone separately. At 35 days after MI, compared with vehicle-treated hearts, capillary numbers in nonischemic zone and infarct borderzone were greater in both iPSC-and iPSC-EV-treated hearts (Figure 7 ). In the infarct zone, compared with vehicle treatment, iPSC-EV injection, but not iPSC injection, resulted in significantly greater capillary numbers. These data indicate that intramyocardial delivery of both iPSCs and iPSC-EVs promotes angiogenesis in infarct border zone and nonischemic zone, whereas iPSC-EV therapy extends neovascularization in the infarct zone as well.
Effects on Viable Myocardium Within the Infarct Zone and Myocyte Apoptosis
The effects of reparative therapies with regard to potential cellular replacement and myocyte salvage were assessed quantitatively. Myocytes constituted 45.1±1.2%, 51.4±2.7%, and 53.1±1.6% of the infarct zone in groups I, II, and III, respectively ( Figure 8A through 8D) ; therefore, the amount of viable myocardium in the infarct zone was, on average, 14% and 18% greater in iPSC-and iPSC-EV-treated mice compared with vehicle-treated mice, respectively (both P<0.05 versus vehicle-treated group). However, there was no significant difference between iPSCs and iPSC-EVs groups.
In the infarct zone, the percentage of TUNEL-positive apoptotic cardiomyocyte nuclei was similar in groups I and II, whereas iPSC-EV treatment reduced apoptosis modestly yet significantly ( Figure 8E and 8F ). In the borderzone and nonischemic zone, compared with vehicle injection, iPSC injection reduced the percentage of apoptotic myocytes minimally, whereas iPSC-EV injection was associated with significant reduction in myocyte apoptosis. These data indicate that intramyocardial delivery of iPSC-EVs protects against myocyte apoptosis during postinfarct remodeling.
Intramyocardial Delivery of iPSCs Induced Teratoma Formation
Development of cardiac tumor was noted in a large number of mice (8 of 15; 53%) in the iPSC-treated group. Gross morphological features, variegated tissue composition, and histological characteristics suggesting differentiation into derivatives of all 3 germ layers identified these tumors as teratomas ( Figure 8G ; Online Figure XI ). No such tumor was noted in any mouse in iPSC-EV-or vehicle-injected groups.
Discussion
Although numerous strategies for cell-based cardiac repair have been tested in patients with ischemic heart disease, the benefits of such therapies are still only modest in clinical trials. 1, 24 Growing evidence indicates that paracrine effects of EVs released by various cells can protect the endogenous myocardial tissue from cell death and other adverse effects, leading to improved remodeling and preserved function. 8, 25 The current results provide novel information in this regard.
Salient Findings
We performed an extensive multidimensional evaluation of the molecular contents, biological effects, and regenerative capacity of iPSC-EVs, consisting of both ectosomal and exosomal fractions, on cardiac cell function in vitro. For the first time, the safety and cardiac reparative efficacy of iPSC-EVs were directly compared with those of iPSCs in a model of reperfused MI in vivo. Our results show that (1) iPSCs release EVs that carry significant amounts of bioactive contents of the parent cell, along with a distinct set of miRNAs and proteins; (2) iPSC-EVs enhance angiogenic capacity, migratory properties, and survival of heart-derived cells; (3) intramyocardial transplantation of both iPSCs and iPSC-EVs after a reperfused MI improves LV function, albeit iPSC-EVs render superior benefits; (4) the in vitro effects of iPSC-EVs are translated in vivo with reduced myocyte apoptosis and enhanced angiogenesis; and (5) iPSC injection is associated with tumor formation, whereas iPSC-EVs seem safe. Together, these results indicate that injection of bioactive, cell-free, iPSC-EV specimens represents an effective and safe approach for cardiac repair after ischemic injury. Paracrine activities of transplanted cells have been widely implicated in tissue regeneration and heart repair. Indeed, our previous work suggests that adult bone marrow-derived cells improve heart function by increasing new vessel formation and myocardial perfusion because of growth factors released by injected cells. 26, 27 Recent evidence also indicates that tiny vesicles termed EVs carry various bioactive molecules that may ultimately mediate the paracrine effects of stem cells. Although the composition of EV cargo depends on the specific cell type of origin, and influences the EV functional effects on target cells, 28 iPSC-EVs have not been characterized in sufficient detail. Our current data constitute the first comprehensive multi-instrumental analysis of cargo in murine iPSC-EVs and show that iPSC-EVs are enriched in numerous mRNA, miRNA, and proteins that originate from parental iPSCs and also possess a unique set of factors, which may be transferred to cardiac cells. The miRNAs and proteins in iPSC-EVs were related not only to pluripotency but also to activation of cell proliferation, differentiation, and angiogenic activity.
Importantly, we cultured iPSCs in feeder-and serum-free conditions in composition-defined medium, which are crucial factors for the quality and purity of iPSC-EVs. It has been shown that the presence of any serum in EV donor cell culture significantly increased the number of serum-derived particles coisolated with the EV specimens, which may influence the results and data interpretation. 29 Moreover, several laboratories, including ours, have reported major impacts of different expansion media on the molecular composition and biological properties of EVs released by the same type of stem cell, suggesting the critical need for appropriate EV preparation and characterization before their administration. 30, 31 Thus, we selected serumfree, fully defined medium for iPSC culture before iPSC-EV harvest, which simulated closely the GMP standards for cellular expansion for future application in humans. Our results confirm that similar to iPSCs cultured in presence of serum, 32 iPSCs expanded under our defined serum-free conditions preserved pluripotent characteristics (Figure 1 ) and released iPSC-EVs with normal morphology and antigenic phenotype (Figure 2) .
By performing global miRNA analysis, we found >200 regulatory miRNAs in iPSC-EV cargo, including 33 that were enriched in the vesicles when compared with the donor iPSCs (Online Table I ). The miRNAs enriched in iPSC-EVs included the miR-145, let-7 family, and miR-302a-5p that are known to regulate cell proliferation, differentiation, as well as self-renewal and pluripotency. 19 Moreover, the iPSC-EVenriched miRNAs were accompanied with other transcripts common for iPSCs, including miR-290-295 embryonic cluster regulating pluripotency, 19, 33 as well as miR-19b, miR-20a, miR-126-3p, miR-130a-3p, miR-210-3p, and embryonic longevimir cluster miR-17-92, which promote angiogenesis, adaptation to hypoxic stress, regulation of cell cycle, mammalian development, and aging. 20 These data suggest potential regulatory effects of iPSC-EVs on survival, neovascularization, and proregenerative properties after the transfer of such miRNAs into cardiac cells.
Consistent with these findings at the miRNA level, we not only found ≈2000 proteins that were common for iPSC-EVs and their parental cells but also ≈200 proteins, which were enriched in iPSC-EVs. The GO analysis identified sets of proteins enriched in iPSC-EVs, which are involved in response to external stimuli, wound healing, regulation of cell differentiation, as well as development of organs and multicellular organisms (Figure 3 ; Online Figure VIA) . Importantly, several proteins involved in angiogenesis and remodeling were identified as node proteins within the network (Online Figure VII) . Together, the current proteomic data identify key novel components of the iPSC-EV cargo that may exert reparative effects in vivo.
The above findings also indicate that the contents of iPSCs are efficiently transferred into EVs, thereby enabling these vesicles as conveyors of iPSC molecular properties. The potential role of EVs in transfer of proregenerative functions to target cells was confirmed by increased angiogenic capacity, migratory ability, and resistance to apoptosis of CECs after exposure to iPSC-EVs (Figure 4 ). These data also extend our previous observations on the transfer of bioactive cargo from human iPSC-EVs to primary cardiac mesenchymal cells, thereby improving their proliferation, metabolic activity, as well as angiogenic and cardiomyogenic differentiation. 3 Furthermore, these molecular findings provide plausible mechanisms underlying the iPSC-EV-induced benefits after injection into the infarcted heart, which include (1) enhanced angiogenesis, which in turn leads to superior remodeling; (2) reduced apoptosis, which leads to greater preservation of myocytes within the scar region; and (3) reduced fibrosis, which leads to improved remodeling and reduced LV mass. However, based on the size criteria, iPSC-EVs used in this study contained both ectosomes and exosomes, described as distinct EV subpopulations in terms of biogenesis, size, molecular contents, and function. 34 The potential differences in bioactive molecular contents between these 2 fractions and the mechanistic implications thereof with regard to heart repair by each fraction separately remain to be explored.
Although both iPSCs and EVs have been used for cardiac repair, each has unique advantages and disadvantages. Therefore, we felt it was important to directly compare the outcomes of cardiac repair with iPSCs and iPSC-EVs in vivo. Although both improved LV function, the benefits of iPSCEVs were more pronounced. In addition, the improvement in LV remodeling was superior with iPSC-EVs. This was evident in smaller LV end-systolic volume and LV mass in iPSC-EV-treated mice. Although iPSC-EV injection also reduced interstitial fibrosis by 11%, this did not reach statistical significance. Furthermore, iPSC-EV injection enhanced capillary density in the infarct zone, which may enhance the quality of scar and further improve remodeling during longer follow-up. This effect may directly relate to the transference of proangiogenic properties by iPSC-EVs to host myocardial cells.
The reduced incidence of myocyte apoptosis in hearts injected with iPSC-EVs constitutes another important observation. These findings are consistent with the in vitro findings of greater survival of CECs after incubation with iPSC-EVs. Similar cytoprotective effects of iPSC-EVs were noted in a previous study by Wang et al, 35 However, in that study, exosomes were injected immediately after the coronary occlusion and before reperfusion was achieved. The reduction of apoptosis with exosome therapy was noted after 24 hours. The authors reported reduced myocardial injury, which was explained predominantly by cytoprotective effects mediated by miR-21 and miR-210 transferred from exosomes to cardiac cells. 35 Our results show, for the first time, that iPSC-EVs confer cytoprotective benefits even when administered after reperfusion injury has set in and these benefits persist during longer follow-up. Although several miRNAs have been implicated in cytoprotection, miRNAs from the miR-17-92 cluster (eg, miR-19a, miR-19b, and miR-20a) noted in high concentration in iPSCEVs may be responsible for this observation. 36 Moreover, the miR-17-92 cluster also enhances angiogenesis, 37 which may contribute toward improvement in heart function after iPSC-EV injection. Consistently, our proteomic data also indicated the enrichment of several proangiogenic molecules in iPSCEVs, including BMP-4, PDGFα, TDGF1, thrombospondin-1, and VEGF-C. This enrichment of the molecular contents of iPSC-EVs with proangiogenic and cytoprotective agents may explain the beneficial effects observed in vivo.
Finally, the direct comparison of iPSCs and iPSC-EVs also brings to light a vitally important finding with regard to safety of regenerative therapy. Although the follow-up duration was only 6 weeks, 8 of 15 mice injected with iPSCs developed teratomas within various cardiac structures. No such neoplastic transformation was noted in the other 2 groups. Teratoma formation by iPSCs after injection in vivo is a well-known phenomenon related to the pluripotent state of these cells and has been observed in several prior studies. 11, 38, 39 This phenomenon is currently one of the major hurdles for therapeutic application of iPSCs for tissue regeneration in humans. Our findings show that even though the injection of parental iPSCs remains hazardous, superior reparative benefits may be achieved safely with the injection of EVs derived from those same cells.
Conclusions
The current findings provide comprehensive evidence that iP-SC-EVs represent bioactive specimens that carry unique payloads of molecules released by donor iPSCs, which may be transferred to cardiac cells resulting in enhancement of biological functions. Further, the first systematic comparison of iPSCs and iPSC-EVs in vivo reveals superior efficacy of iPSC-EVs for cytoprotection, vascularization, and cardiac repair. Finally, the absence of tumor formation in the iPSC-EV group advances the potential candidacy of the same for safe and effective heart repair after ischemic myocardial injury in humans. 
